Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorder Clear all

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: semaglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 72
States / cities: Phoenix, Arizona • Anaheim, California • Fresno, California + 63 more

Conditions: Leukemia, Acute Lymphoblastic, Leukemia
Interventions: Not listed
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 1 Year to 24 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions: DCDT2980S, rituximab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 9
States / cities: Stanford, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Proliferative Vitreoretinopathy
Interventions: Isotretinoin; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years to 80 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Kidney Disease Stages 3-5
Interventions: Ergocalciferol supplementation; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Parkinson's Disease, Depression
Interventions: Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 35 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Endogenous Cushing Syndrome, Adrenal Insufficiency, Hypercortisolism
Interventions: Osilodrostat; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: AZD4360; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Santa Monica, California • Providence, Rhode Island • Houston, Texas

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Interventions: WHOOP strap 3.0; Device
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Alzheimer's Disease
Interventions: Placebo, octagam 10%; Drug · Biological
Lead sponsor: Octapharma; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hoboken, New Jersey

Conditions: Unemployment
Interventions: Purposeful Pathways, Transitional Work Experience; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bedford, Massachusetts

Conditions: Breast Cancer, Arthralgia
Interventions: Exercise, Attention Control (Health Education); Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale, PIVSD - Post Infarct Muscular Ventricular Septal Defect, Valvular Heart Disease
Interventions: Amplatzer™ Occlusion Devices, Epic™ Surgical Tissue Heart Valve devices; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 9 more

Conditions: Reproductive Disorder
Interventions: kisspeptin 112-121, GnRH; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: RAD 001; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Prostate Cancer, Breast Cancer Female
Interventions: Exercise; Behavioral
Lead sponsor: Celina Shirazipour; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
Interventions: brentuximab vedotin, rituximab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 33
States / cities: Birmingham, Alabama • Duarte, California • Oxnard, California + 26 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: filgrastim, dexamethasone, melphalan, thalidomide; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer's Disease
Interventions: icosapent ethyl (IPE), gel cap placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 75 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Alcohol Abuse, Cannabis Abuse, Nicotine Dependence
Interventions: c-ASBI; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 9 Years to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 6
States / cities: Boston, Massachusetts • Cambridge, Massachusetts • Lexington, Massachusetts

Conditions: Anemia
Interventions: Roxadustat, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 2,781 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 97
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 72 more

Conditions: Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
Interventions: Not listed
Lead sponsor: Neurogen Biomarking LLC; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Chicago, Illinois • Dearborn, Michigan • Flint, Michigan + 2 more

Conditions: Parkinson Disease, Dystonia, Autonomic Dysreflexia
Interventions: osteopathic manual therapy; Other
Lead sponsor: New York Institute of Technology; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Old Westbury, New York

Conditions: Multiple Myeloma, Plasma Cell Neoplasm
Interventions: Lenalidomide, Dexamethasone, Anticoagulants; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 16
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more

Search by objective public record fields.

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Vincristine PK and PD in the AYA Population Compared to Younger Children

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

Isotretinoin for Proliferative Vitreoretinopathy

Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose

Cognitive Behavioral Therapy for Depression in Parkinson's Disease

A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement

Study for AZD4360 in Participants With Advanced Solid Tumours

Wearable Remote Monitoring of Heart Rate and Respiratory Rate for Heart Failure

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

Improving Vocational Outcomes of Veterans With Psychiatric Disorders: Career Counseling & Development

Hormones and Physical Exercise (HOPE) Study

Abbott Structural Heart Device Registry

Recall by Genotype: Neuropeptide Stimulation

Trial of RAD001 in Triple Negative Metastatic Breast Cancer

Streaming Web-based Exercise At Home: A Pilot Study

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

Trial of Computerized SBI to Reduce Teen Alcohol Use

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

Osteopathic Manual Treatment Parkinson's Disease and Truncal Dystonia

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction